Willow tree capital presentation july 2015
-
Upload
david-murayama -
Category
Documents
-
view
219 -
download
5
description
Transcript of Willow tree capital presentation july 2015
CORPORATE PRESENTATION
www.willowtreecapital.com
LicensingM&AStrategic
Consulting
July 2015
Due DiligenceCapital Markets
Financial Valuations
c
c
Willow Tree Capital Group | 2015
About Willow Tree
2
WILLOW TREE CAPITAL GROUP is a boutique Investment
bank with a highly experienced team of multidisciplinary specialists devoted
to the life science industry. Our team – with practical expertise in healthcare,
science, business and capital markets – has completed Billions of dollars of
transaction value.
The team’s breadth of industry knowledge and collective leadership
experience enable us to deliver comprehensive strategic advisory services
throughout the business process.
We are well positioned to navigate through every step of complex
transactions, with clients ranging from early-stage biotech to big pharma.
c
c
Willow Tree Capital Group | 2015
Our Culture
3
Willow Tree Capital is an
unconventional investment bank with a
disciplined and entrepreneurial approach
to servicing our clients.
Our team has worked in the
Pharma/Biotech industry and owned &
operated our own businesses – leading to
a creative and fearless approach to
problem solving and driving through the
process.
This approach has led to a pipeline of LOI
negotiations in excess of $7B.
“I have had the pleasure of working with Willow Tree Capital Group on an acquisition project. Their team was knowledgeable, creative and resourceful in their approach. I will look to engage them again in future projects, and recommend working with them on either the buy or sell side of pharmaceutical assets.”
Bill Wells, former CEO of Biovail & Chairman of Valeant Pharmaceuticals
c
c
Willow Tree Capital Group | 2015
360° Perspective
4
We are comprised of pharma and non-pharma business experts that provide our clients with a unique 360° perspective and collaborative approach.
Willow Tree’s valuation and forecasting methodology is proven, disciplined and reliable.
Clients value our creative and innovative approach to business. Our unique outlook offers us competitive advantages in negotiations and in building strategic partnerships.
We have a global reach with strong international partners, team members and alliances.
“I have known Willow Tree Capital Group since its inception. The team embodies all the essential qualities of success: That rare combination of an astute capacity to see how medical/pharmaceutical assets create a business around an opportunity. These qualities in combination with exceptional management skills and integrity makes it a privilege for SOM Biotech to work with WTC.”
Raúl Insa, MD, PhD, MBA, CEO of SOM Biotech – Spain
c
c
Willow Tree Capital Group | 2015
Willow Tree Services
5
With a global presence, Willow Tree provides life science companies
with strategic advice and hands-on assistance with:
LicensingM&AStrategic
Consulting
Due DiligenceFinancial
ValuationsCapitalMarkets
Biotechnology Pharmaceuticals Medical Devices
Manufacturing Facilities Animal Health Medical Diagnostics
c
c
Willow Tree Capital Group | 2015
Willow Tree Expertise
6
Our team has extensive knowledge providing:
• Strategic business direction
• Arranging in- and out-licensing
• Advising on asset acquisitions and divestitures
• Capital raising
• Scientific and financial due diligence
• Financial valuations
Our extensive global relationships assist our corporate clients with
their capital markets needs.
We advise new biotech/pharma clients to implement strategic plans
and navigate through complex purchasing rights.
c
c
Willow Tree Capital Group | 2015
Leverage Our Expertise
Our Firm Brings Hands-On Industry Experience
US$7B+ in LOI / Term
Sheet Negotiations
US$3B+ transactions
completed by team
Clients include seed-
biotech to big pharma
Global transactional
experience
Extended team with
solid life sciences
credentials
Decades of relevant
global industry
experience
Over 75 peer reviewed
publications
Successful entrepreneur
exits
90+ years experience in
corporate growth
strategies
Extensive global
networks
Expert company and
product financial modelling / valuation
7
c
c
Willow Tree Capital Group | 2015
Transactional Experience
Inhale Therapeutics / Bradford Particle Design (UK): $200M (public / private; stock & cash)
Agilent / Stratagene: $245M (public / public; all cash)
Agilent / J&W Scientific: $45M (public / private; all cash)
Inhale Therapeutics / Shearwater Corp: $170M, (public / private; stock + cash)
GTI / Perlegen Sciences: $ undisclosed (private / private; all cash)
J&W Scientific / Unimetrics: $ undisclosed (private / private; all cash)
Concordia / Pinnacle Biologics US Corp: $60M (public / private; all cash)
Dermatology Company divested to Large Pharma: $ undisclosed (private / public; all cash)
$2B+ in public and private financings and non-pharma M&A
8
Our team brings an impressive deal portfolio with Billions of dollars
in International transactional experience:
MERGERS, ACQUISITIONS & DIVESTITURES
9
c
c
Willow Tree Capital Group | 2015
Mergers, Acquisitions & Divestitures
Willow Tree Provides:
Corporate Strategy, due diligence, and valuation services needed to empower
transactional goals
Sell Side - Anonymous searches for strategic buyers for optimal asset monetization
Buy Side - Anonymous searches for acquisition targets aligned with company’s
growth strategy
Commercial and strategic experience in the healthcare sector to facilitate the buy or
sell process for:
• Ongoing Entities
• IP Portfolio Monetization
• Mature Product Lines
• Capital Asset Sales
• Facilities & Other PPE
• Cross-border Transactions
10
STRATEGIC CONSULTING
11
c
c
Willow Tree Capital Group | 2015
Strategic Consulting
Willow Tree’s principals are former business executives with entrepreneurial,
Fortune 500, capital markets and life science expertise. We provide
comprehensive consulting services, including:
Company & Asset Valuation
Pipeline & Product Review
Clinical & Commercial Strategy
Life Cycle Management
Strategic & Tactical Business
Planning
12
Willow Tree provides its clients with stand alone consulting services or as
part of a actionable strategic plan for future divestitures, licensing or M&A
transactions.
LICENSING
13
c
c
Willow Tree Capital Group | 2015
Product & Technology Licensing
Licensing strategy development at all
development phases
Out-licensing collateral preparation
Targeted asset search and in-licensing
License valuation and structuring
Term sheet and contract development,
negotiation and execution
License Portfolio Management Service
14
Willow Tree’s principals have significant experience as corporate and research
institution licensing executives.
Experience and ability to identify the appropriate asset/licensor for each client,
among the numerous and broad licensing opportunities available. The team has
notable skills in:
CAPITAL MARKETS EXPERTISE
15
c
c
Willow Tree Capital Group | 2015
Capital Markets Expertise
Investor Roadshows
Arranging global financing
syndicates for:
IPOs
Secondary Offerings
Private Equity
RTOs / CPCs
Debt Financing
Mezzanine Financing
Structured Products
16
Willow Tree executives have financed Billions in debt and equity for public
and private corporations. They have provided the following capital
markets services:
THE WILLOW TREE CORE TEAM
17
c
c
Willow Tree Capital Group | 2015
The Willow Tree Core Team
Cathy Miner, BA/BPHE; Managing Partner
Rich Goodman, JD, MBA; Managing Partner
David Young, MSc; Managing Director
Kevin Cooksy, DiplSc, JD, MBA; Managing Director
David Murayama, MBET; Business Strategy and Operations Manager
Dr. Firhan Malik, PhD, MSc; Business Development
Michael Pettigrew, BASc; Business Development
18
c
c
Willow Tree Capital Group | 2015
Willow Tree Core Team Bios
Cathy Miner, Managing PartnerBA / BPHE
Cathy Miner has over 25 years of Fortune 500 and
entrepreneurial business experience. In 1999 Cathy
founded Vital Science Corp. and developed the skincare
line dermaglow™. This company was eventually targeted
by and sold to Valeant Pharmaceuticals in 2010. At the
time of the sale, dermaglow™ was selling in retail outlets
throughout Canada, France, Sweden, Finland, the Middle
East and Greece.
Before founding Willow Tree Capital (WTC) in 2013,
Cathy worked at Distinct Capital Corp. as Managing
Director where she provided investment banking services
including M&A, corporate finance and business
advisory. Ms. Miner’s experience includes extensive
experience in acquisitions, licensing, divestitures,
negotiations and fund raising. Represented WTC with
LOIs and Term Sheets in excess of $7B.
Ms. Miner has received many awards over the years for
her outstanding business performance. Ms. Miner is an
Honors graduate at Queen’s University.
Rich Goodman, Managing Partner JD, MBA
Rich Goodman is a capital markets professional that has
participated in billions of dollars of financings and M&A
transactions in numerous sectors, including life sciences,
technology, resources, consumer products, agriculture,
aerospace and industrial. He has provided transactional
advice to his corporate clients for over two decades.
Prior to joining Willow Tree, Rich was Head of Investment
Banking at Octagon Capital – advising clients on financings,
IPOs, acquisitions, asset sales, valuations, and corporate
strategy. Prior to that, he practiced securities law at
McMillan LLP, providing legal advice on corporate financings
and M&A transactions.
Rich holds a Juris Doctor (JD) from Western University,
Masters in Business Administration (MBA) from the Richard
Ivey School of Business, and a Bachelor of Arts (BA), major
in Economics, from York University. He is a member of the
Law Society of Upper Canada.
[email protected] [email protected]
416.569.5105 416.399.4225
19
c
c
Willow Tree Capital Group | 2015
Willow Tree Core Team Bios
David Young, Managing Director
BSc, MSc
David Young has a diverse background in the
biotechnology and pharmaceutical industries over the
last 25+ years; including R&D, manufacturing, sales and
business development. As the Sales Manager for a
leading Canadian biopharmaceutical company, he
developed a global client base in North America, Europe
and Japan and helped to build them into a leading
player in the biopharmaceutical CMO market. As the
National Sales Manager in Canada for this company, he
helped to grow their HepaGam B product into a market
leader and also to expand their market-leading WinRho
product into a new indication.
At Willow Tree, David has run the process to find
licensing partners, negotiating termsheets, research
agreements and licensing deals with buyers. David also
led projects for licensing and divestiture of oncology
assets, manufacturing facility divestitures and consulting
for pharmaceutical product development.
David studied Biochemistry at Queen’s University,
earning a BSc and an MSc. The focus of his Masters
work was protein biochemistry and molecular biology.
Kevin Cooksy, Managing Director,
JD, DiplSc, MBA
Kevin Cooksy brings over twenty years of experience as
a life sciences and biotechnology industry executive,
serving in leadership roles in global business
and corporate development. Kevin’s transaction
portfolio, which exceeds a billion USD, includes buy
and sell M&A, complex licensing, and IP portfolio
optimization for diverse entities in the drug engineering
and drug delivery, medical device, and biologics
segments. Kevin’s experience with publicly-traded and
private entities includes, among many others, Agilent
Technologies’ acquisition of Stratagene Corporation, a
premier reagents manufacturer, and Inhale
Therapeutics’ acquisition of Shearwater Corporation, a
leader in molecule enhancement for improved drug
uptake and life cycle management.
Kevin holds a BSc from Northern Illinois in chemistry
(honors research), a DiplSc in Translational Medicine
from the University of Edinburgh School of Medicine
(distinction), an MBA from Lake Forest College (finance,
high honors), and a JD from the University of the
Pacific’s McGeorge School of Law (moot court honors).
[email protected] [email protected]
20
c
c
Willow Tree Capital Group | 2015
Willow Tree Core Team Bios
David Murayama, Business Strategy & Operations Manager
BSc, MBET
David has extensive experience in international relations. David was actively engaged in consulting for CPP, a biotechnology
company under MaRS Innovation, while in the MBET program at Waterloo. Prior to the MBET program, he worked at the
Permanent Mexican Mission to the United Nations within the green economy sector as well as his own sports-focused social
network startup.
David received a BSc in Economics (International Econ.) from Suffolk University in Boston and a Masters of Business,
Entrepreneurship and Technology (MBET) from the University of Waterloo.
Dr. Firhan Malik, Business Development Associate
BSc, MSc, PhD
Firhan has over 10 years of experience in academic
research, and 8 years as a graduate student researcher in
the University of Toronto’s Faculty of Medicine. He
studied cystic fibrosis and congestive heart failure at the
Hospital for Sick Children, the Heart and Stroke Richard
Lewar Center in Excellence, and the MaRS Discovery
District. Firhan has extensive knowledge in the use of
novel therapeutics (e.g., orphan drugs) in cell models, and
the scale up of these therapeutics into animal models.
Firhan received his BSc (Honours) in Biochemistry from
Laurentian University, and his MSc in Biochemistry and
his PhD in Physiology at the University of Toronto. His
work has been funded by the Natural Sciences and
Engineering Research Council (NSERC) of Canada.
Michael Pettigrew, Business Development Associate
BASc
Michael brings expertise in biomedical engineering and the life
sciences to Willow Tree. He has held research positions in the
fields of synthetic biology and neural engineering, and
received a number of awards during his studies at the
University of Toronto for both his research and academics.
Michael is a co-founder of a company that develops
automated laboratory instruments to measure cellular lifespan.
He developed the company’s patent-pending technology.
Michael has a deep understanding of science and what it
takes to invent, build a company, raise capital and out-license
the technology.
Michael received an Honours BASc in Biomedical Engineering
and an Engineering Business Certificate from the University of
Toronto.
21
Contact Us:
www.willowtreecapital.com
Cathy Miner - Managing [email protected]
Rich Goodman - Managing [email protected]
LicensingM&AStrategic
Consulting
Due DiligenceCapital Markets
Financial Valuations